EZE-Gluc to Identify At-Risk Patients

Case ID:

This technology is a functional test to assess which patients will have toxicity to drugs that use the same transporters as ezetimibe glucuronide, or EZE-Gluc. By administering ezetimibe, a commonly used drug, as a predictive diagnostic tool, healthcare providers can gauge the likelihood of treatment success for various medications. The key lies in measuring the levels of a specific metabolite, EZE-Gluc, in either urine or blood samples. This metabolite's behavior shifts in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH), affecting its elimination process. Normally eliminated through bile, in MASH patients, it tends to accumulate in plasma and urine instead. Understanding how EZE-Gluc behaves in MASH patients provides valuable insights into the functioning of crucial transport processes in the body. These processes not only impact the efficacy of ezetimibe but also influence the disposition of other drugs that share the same transport mechanisms. By conducting tests to assess EZE-Gluc levels before initiating treatment with drugs like pemetrexed, methotrexate, sorafenib, and others, healthcare providers can identify patients who might be at risk of adverse reactions or altered therapeutic outcomes. 

The technology addresses the challenge of predicting the effectiveness and potential adverse reactions of various drugs, particularly in patients with conditions like Metabolic dysfunction-Associated SteatoHepatitis (MASH). Currently, healthcare providers rely on trial and error or general guidelines to determine the most suitable treatment for individual patients. However, this approach can lead to inefficiencies, suboptimal outcomes, and even harmful side effects. Existing methods for assessing drug efficacy and toxicity typically involve monitoring symptoms, conducting laboratory tests, or adjusting dosages based on observed reactions. By using ezetimibe as a predictive diagnostic tool and measuring the levels of its metabolite, EZE-Gluc, healthcare providers gain valuable insights into the patient's ability to transport and eliminate certain drugs. This information allows for more targeted treatment plans, potentially reducing the risk of adverse reactions and improving therapeutic outcomes. Unlike current technologies, which often rely on generalized guidelines or reactive measures, this approach enables proactive decision-making tailored to the individual patient's physiology and medical history.


  • Metabolic Dysfunction-Associated Steatohepatitis diagnostic
  • Pharmacogenomics
  • Personalized medicine
  • Drug development and testing


  • Enhanced predictive capability for drug effectiveness and adverse reactions
  • Better understanding of transport processes in vivo
Patent Information:
Contact For More Information:
Garrett Edmunds
Licensing Manager, UAHS-TLA
The University of Arizona
Lead Inventor(s):
Nathan Cherrington